14.21
price up icon1.65%   0.23
 
loading
Neogenomics Inc stock is traded at $14.21, with a volume of 885.14K. It is up +1.65% in the last 24 hours and down -19.03% over the past month. NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
See More
Previous Close:
$13.98
Open:
$14.12
24h Volume:
885.14K
Relative Volume:
1.16
Market Cap:
$1.82B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-22.92
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-3.79%
1M Performance:
-19.03%
6M Performance:
-8.32%
1Y Performance:
-8.09%
1-Day Range:
Value
$14.01
$14.57
1-Week Range:
Value
$12.12
$16.18
52-Week Range:
Value
$12.12
$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name
Name
Neogenomics Inc
Name
Phone
(239) 768-0600
Name
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Name
Employee
2,100
Name
Twitter
@NeoGenomics
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
NEO's Discussions on Twitter

Compare NEO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
NEO
Neogenomics Inc
14.21 1.82B 628.25M -78.55M -29.73M -0.62
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
559.65 214.07B 42.37B 6.14B 7.78B 15.95
Diagnostics & Research icon
DHR
Danaher Corp
238.36 172.16B 23.74B 3.89B 4.98B 5.24
Diagnostics & Research icon
A
Agilent Technologies Inc
147.36 42.09B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
197.36 35.82B 15.32B 1.41B 1.96B 7.62
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
419.26 34.33B 3.84B 866.24M 792.60M 10.37

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-13-25 Downgrade The Benchmark Company Buy → Hold
Dec-10-24 Initiated Jefferies Buy
May-01-24 Resumed Craig Hallum Buy
Dec-29-23 Reiterated BTIG Research Buy
Aug-21-23 Upgrade Stephens Equal-Weight → Overweight
May-16-23 Downgrade Raymond James Outperform → Mkt Perform
May-09-23 Upgrade BTIG Research Neutral → Buy
Feb-24-23 Upgrade The Benchmark Company Hold → Buy
Feb-01-23 Upgrade Needham Hold → Buy
Aug-26-22 Downgrade The Benchmark Company Buy → Hold
Aug-22-22 Downgrade Needham Buy → Hold
Jun-03-22 Initiated Piper Sandler Overweight
Mar-29-22 Downgrade BofA Securities Buy → Neutral
Mar-29-22 Downgrade Stephens Overweight → Equal-Weight
Jan-18-22 Resumed Stephens Overweight
Dec-16-21 Initiated Cowen Outperform
Nov-05-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-14-21 Upgrade Raymond James Mkt Perform → Outperform
Jun-03-21 Initiated Goldman Buy
Feb-25-21 Resumed Needham Buy
Feb-25-21 Downgrade Raymond James Outperform → Mkt Perform
Jan-28-21 Initiated Truist Buy
Dec-11-20 Resumed BTIG Research Buy
Oct-28-20 Reiterated Needham Buy
Sep-09-20 Initiated Morgan Stanley Overweight
Aug-28-20 Initiated Guggenheim Buy
Jul-29-20 Reiterated Needham Buy
Jun-25-20 Initiated BofA/Merrill Buy
Apr-21-20 Resumed Stephens Overweight
Mar-02-20 Resumed Craig Hallum Buy
Feb-28-20 Upgrade First Analysis Sec Outperform → Strong Buy
Jan-23-20 Downgrade First Analysis Sec Strong Buy → Outperform
Oct-30-19 Reiterated Needham Buy
May-01-19 Reiterated Needham Buy
Mar-29-19 Reiterated Needham Buy
Jan-03-19 Initiated Needham Buy
Oct-24-18 Upgrade First Analysis Sec Outperform → Strong Buy
Aug-21-18 Initiated Leerink Partners Outperform
May-02-18 Downgrade First Analysis Sec Overweight → Equal-Weight
Sep-11-17 Downgrade BTIG Research Buy → Neutral
Aug-24-17 Initiated Gabelli & Co Buy
Dec-15-16 Initiated Cantor Fitzgerald Overweight
View All

Neogenomics Inc Stock (NEO) Latest News

pulisher
Jan 19, 2025

Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $20.30 - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast - MSN

Jan 18, 2025
pulisher
Jan 16, 2025

NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast By Investing.com - Investing.com Canada

Jan 16, 2025
pulisher
Jan 16, 2025

Neogenomics stock sees solid support from Needham on updated guidance and expansion plans - Investing.com Canada

Jan 16, 2025
pulisher
Jan 15, 2025

NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance - Yahoo! Voices

Jan 15, 2025
pulisher
Jan 15, 2025

Medtech Surges, Reversing CEO-Tied Selloff, On Long-Term Guide - Investor's Business Daily

Jan 15, 2025
pulisher
Jan 15, 2025

NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 15, 2025
pulisher
Jan 15, 2025

5 Analysts Assess NeoGenomics: What You Need To Know - Benzinga

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics (NASDAQ:NEO) Shares Gap UpStill a Buy? - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics rises on upbeat sales outlook for 2025 - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics stock rises on upbeat 2025 financial outlook By Investing.com - Investing.com Nigeria

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics stock rises on upbeat 2025 financial outlook - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics Announces Executive Bonuses and Revenue Growth - TipRanks

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - The Bakersfield Californian

Jan 15, 2025
pulisher
Jan 15, 2025

NeoGenomics Projects Strong Growth: 43-51% EBITDA Jump, $735M+ Revenue Target for 2025 - StockTitan

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptive, NeoGenomics partner to expand access to disease monitoring - MSN

Jan 15, 2025
pulisher
Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand - GlobeNewswire

Jan 14, 2025
pulisher
Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha

Jan 14, 2025
pulisher
Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - The Manila Times

Jan 14, 2025
pulisher
Jan 14, 2025

Adaptive Biotech Partners with NeoGenomics to Transform Blood Cancer Testing with clonoSEQ - StockTitan

Jan 14, 2025
pulisher
Jan 14, 2025

What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash - Simply Wall St

Jan 14, 2025
pulisher
Jan 14, 2025

NeoGenomics (NASDAQ:NEO) Sets New 52-Week LowWhat's Next? - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

NeoGenomics Inc (NEO) Trading Down 14.52% on Jan 13 - GuruFocus.com

Jan 14, 2025
pulisher
Jan 13, 2025

NeoGenomics (NASDAQ:NEO) Trading Down 8%Here's What Happened - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

NeoGenomics (NASDAQ:NEO) Downgraded by Benchmark to Hold - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

NeoGenomics price target lowered to $18 from $21 at BTIG - MSN

Jan 12, 2025
pulisher
Jan 12, 2025

NeoGenomics CEO Chris Smith to retire - MSN

Jan 12, 2025
pulisher
Jan 10, 2025

NeoGenomics announces CEO succession plan - Gulfshore Business

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics CEO change prompts Raymond James to hold rating By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 10, 2025

Neogenomics stock holds $19 target despite CEO change By Investing.com - Investing.com UK

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics CEO steps down, shares fall 17% By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics Shares Fall on CEO's Plan to Retire - MarketWatch

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics (NEO) Shares Cross Below 200 DMA - Nasdaq

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics Shares Are Falling Today: What's Going On? - Benzinga

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics (NASDAQ:NEO) Shares Gap DownWhat's Next? - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics (NEO) CEO Chris Smith to retire - StreetInsider.com

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics, Inc. Reaffirms Earnings Guidance for Full Year Ended December 31, 2024 - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics Appoints Tony Zook As CEO - citybiz

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm - MarketWatch

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics Announces CEO Transition and Leadership Change - TipRanks

Jan 10, 2025
pulisher
Jan 10, 2025

NeoGenomics Announces Chief Executive Officer Succession - The Bakersfield Californian

Jan 10, 2025
pulisher
Jan 10, 2025

Neogenomics, Announces Retirement of Chris Smith as Board Member, Effective April 1, 2025 - Marketscreener.com

Jan 10, 2025
pulisher
Jan 09, 2025

FY2024 EPS Estimates for NeoGenomics Increased by Analyst - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

NeoGenomics (NASDAQ:NEO) Sets New 12-Month HighShould You Buy? - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

NeoGenomics stock hits 52-week high at $19.01 amid growth By Investing.com - Investing.com Australia

Jan 09, 2025
pulisher
Jan 08, 2025

NeoGenomics stock hits 52-week high at $19.01 amid growth - Investing.com

Jan 08, 2025

Neogenomics Inc Stock (NEO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$158.36
price down icon 6.02%
diagnostics_research LH
$238.56
price down icon 0.09%
$136.67
price down icon 0.51%
diagnostics_research WAT
$404.00
price down icon 0.35%
diagnostics_research MTD
$1,295.43
price down icon 0.16%
$419.26
price down icon 2.18%
Cap:     |  Volume (24h):